Search results
Jun 24, 2024 · We are enabling affordable access to lifesaving biosimilars worldwide. Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
Jun 24, 2024 · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Biocon Biologics Limited (BBL) is a subsidiary of the publicly listed Biocon Limited, which operates its biosimilars business through BBL. Please refer to the Investors’ Section of Biocon Limited for all statutory information.
Biocon Biologics is a subsidiary of Biocon with a focus on Biocon’s Biosimilars business. It is advancing a range of high-quality, safe and effective biosimilars that offer affordable solutions to expensive biologic medicines.
Jun 24, 2024 · Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept. The company expects to include 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. ...
Biocon Biologics Ltd on Monday announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies ...
Jun 24, 2024 · Bengaluru: Biocon Biologics Ltd (BBL), a biosimilars company announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab. It is a type of ...
